Safety and Efficacy Study of Oral XIGO Tablets to Treat The Common Cold

Common Cold Clinical Trial

Official title:

XIGO Effectiveness Study: An Investigation of the Safety and Efficacy of Oral XIGO Tablets on Patients Diagnosed With the Common Cold

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT01092039
• Other study ID #: XIGO-001
• Status: Completed
• Phase: N/A
• First received: March 22, 2010
• Last updated: July 23, 2012
• Start date: March 2010
• Est. completion date: April 2011

Study information

• Verified date: June 2011
• Source: Xigo Health LLC
• Contact: n/a
• Is FDA regulated: No
• Health authority: United States: Institutional Review Board
• Study type: Interventional

Clinical Trial Summary

The purpose of the study will be to assess the efficacy and safety of XIGO administered orally, three times a day, compared with placebo in patients with the common cold.

Description:

The common cold is one of the most frequent human illnesses and has been shown to result in significant morbidity and economic loss. At the present time no truly effective therapy is available. Therapeutic interventions with compounds such as zinc have been found to be helpful however well reported side-effects have prevented its extensive use.

Based on several years of anecdotal clinical evidence which has shown that XIGO is effective in alleviating the symptoms of the common cold-the findings of which are supported by competent and reliable evidence from in vivo and in vitro and clinical trials studies on each of the individual active ingredients of the formulation, it has been proposed that XIGO, when administered orally, has a direct stimulatory effect on multiple components of the immune system. It is proposed that this stimulation increases both the immune cell population as well as its functionality and this will be observed in cells and molecules from both the innate and adaptive responses.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 140
• Est. completion date: April 2011
• Est. primary completion date: March 2011
• Accepts healthy volunteers: Accepts Healthy Volunteers
• Gender: Both
• Age group: 18 Years to 50 Years

Eligibility

Inclusion Criteria:

• Must be in good health in the clinical judgment of the investigator, other than cold symptoms

• Must have a cumulative score of 2 or higher, but not larger than 6, with symptom severity rated as 0=absent, 1=mild, 2= moderate, or 3=severe for each of the eight symptoms: sneezing, nasal discharge, nasal obstruction, sore throat, cough, headache, malaise and chillness. At least one of the first four "cold specific" symptoms must be present, and none of these symptoms can have been present for more than 12 hours.

• Must enter trial within 12 hours of symptoms onset.

• Aged 18-50 years, (inclusive), at visit 1.

• Subjects must understand and sign and date an informed consent form prior to any study related procedures being performed.

• Subjects must be capable of understanding and following directions.

Exclusion Criteria:

• Subjects taking medications, other than birth control, which, in the opinion of the investigator, could influence the purpose, integrity or outcome of the trial.

• Pre-menopausal women (last menstruation <=1 year prior to ICF) who are nursing or pregnant or are of child-bearing potential and, in the opinion of the investigator, are not practicing an acceptable method of birth control, or do not plan to continue using method throughout the study.

• A history of adverse reactions to OTC drugs or other personal care products.

• Subjects who have used systemic steroids for at least 6 weeks prior to trial initiation or during the trial.

• A medical history of autoimmune disease, including Type 1 or Type 2 diabetes or HIV.

• Treatment with immunosuppressive drugs with the exception of cyclosporine for keratitis sicca.

Study Design

Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment

Related Conditions & MeSH terms

• Common Cold

Intervention

Dietary Supplement:
• lactoferrin, L-Glutamine and beta-glucans
Subject will be given XIGO pills or placebo. two tablets to be taken by mouth 3 times per day.
• Placebo Comparator
Subject will be given placebo comparator of two tablets to be taken by mouth 3 times per day.

Locations

Country	Name	City	State
United States	Neccr/Imca Llc	Fall River	Massachusetts

Sponsors (1)

Lead Sponsor	Collaborator
Xigo Health LLC

Country where clinical trial is conducted

United States, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Severity of cold symptoms over 7 days.	The primary outcome measure will be to assess the severity of the typical interrelated common cold symptoms, over the first seven days of observation period, with the first day being the 24 hour period after first dose of treatment, using the patient/subject completion of the Wisconsin Upper Respiratory Symptom Survey-21 (WURSS-21).	7 days post dose	No
Secondary	Severity of Cold Symptoms over 14 days	The secondary outcome measures will be to assess the severity of the typical interrelated common cold symptoms, over the fourteen days of observation period, with the first day being 24 hours after first dose of treatment, using the patient/subject completion of the WURSS-21.	Over 14 day observation period	No
Secondary	Assess time to resolution	This secondary outcome is to assess the time to resolution of the typical interrelated common cold symptoms, with resolution deemed to occur when participant reports being "not sick" for two days in a row	14 days post dose	No
Secondary	Percentage of patients with unresolved symptoms	This secondary outcome is to assess the % of patients with clinically unresolved symptoms at day 14, as accessed by the attending investigator. This will include secondary complications such as rhinitis, sinusitis, lower respiratory tract infections and asthma exacerbations.	14 days post dose	No